Allogeneic Mesenchymal Stem Cells (AlloMSC) ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 1 |
| 53 | Sjogren syndrome | 1 |
51. Scleroderma
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00962923 (ClinicalTrials.gov) | August 2009 | 19/8/2009 | Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc) | Systemic Sclerosis;Mesenchymal Stem Cells | Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | NULL | Recruiting | 15 Years | 65 Years | Both | 20 | Phase 1/Phase 2 | China |
53. Sjogren syndrome
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00953485 (ClinicalTrials.gov) | June 2009 | 4/8/2009 | Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) | Clinical Trial of Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome - Phase ?/? | Sjogren's Syndrome;Mesenchymal Stem Cells | Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | NULL | Recruiting | 15 Years | 70 Years | Both | 20 | Phase 1/Phase 2 | China |